Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
8.75
+0.18 (2.10%)
At close: Mar 20, 2026, 4:00 PM EDT
8.58
-0.17 (-1.94%)
After-hours: Mar 20, 2026, 5:21 PM EDT
Telix Pharmaceuticals Employees
As of December 31, 2025, Telix Pharmaceuticals had 1,184 total employees, including 1,120 full-time and 64 part-time employees. The number of employees increased by 950 or 405.98% compared to the previous year.
Employees
1,184
Change
950
Growth
405.98%
Revenue / Employee
$678,880
Profits / Employee
-$6,018
Market Cap
2.96B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1,184 | - | - | 1,120 | 64 |
| Mar 31, 2024 | 431 | 197 | 84.19% | 415 | 16 |
| Dec 31, 2022 | 234 | 76 | 48.10% | 234 | 0 |
| Dec 31, 2021 | 158 | - | - | 158 | 0 |
| Dec 31, 2017 | 9 | - | - | 9 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Denali Therapeutics | 503 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Dyne Therapeutics | 258 |
| Viridian Therapeutics | 252 |
| Vera Therapeutics | 249 |
| Alumis | 223 |
| Catalyst Pharmaceuticals | 182 |
TLX News
- 1 day ago - Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S. - GlobeNewsWire
- 4 days ago - Telix Pharmaceuticals Limited (TLX) Discusses Revenue Growth, Prostate Cancer Imaging Portfolio, and Expansion into Brain and Kidney Cancer Transcript - Seeking Alpha
- 5 days ago - Telix Resubmits NDA For Brain Cancer Imaging Candidate TLX101-Px To FDA - Nasdaq
- 6 days ago - Telix Resubmits TLX101-Px NDA To FDA For Brain Cancer Imaging Agent - Nasdaq
- 6 days ago - Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate - GlobeNewsWire
- 11 days ago - Why Is Telix Pharmaceuticals Stock Gaining Tuesday? - Benzinga
- 11 days ago - Telix Pharmaceuticals Limited (TLX) Discusses ProstACT Global Phase 3 Study Part 1 Results and Safety Profile Transcript - Seeking Alpha
- 12 days ago - ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives - GlobeNewsWire